Evidence map›Paper›PMID 37842585›Full record

ArticleHeliyon2023

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved.

Tetsuya Suzuki, Yusuke Asai, Kozue Takahashi, Mio Sanada, Yumiko Shimanishi, Mari Terada, Lubna Sato, Makoto Inada, Gen Yamada, Yutaro Akiyama and 13 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Tetsuya SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yusuke AsaiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kozue TakahashiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mio SanadaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yumiko ShimanishiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mari TeradaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Lubna SatoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Makoto InadaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Gen YamadaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yutaro AkiyamaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yusuke OshiroClinical Laboratory Department, National Center for Global Health and Medicine, Tokyo, Japan.
Katsuyuki ShiratoriClinical Laboratory Department, National Center for Global Health and Medicine, Tokyo, Japan.
Tomiteru ToganoDepartment of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.
Yuki TakamatsuDepartment of Refractory Viral Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Maeda KenjiDepartment of Refractory Viral Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiro MatsunagaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Yukihito IshizakaDepartment of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Hidetoshi NomotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KutsunaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinichiro MoriokaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPTohoku University · JPKagoshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We aimed to investigate chronological changes in the characteristics of participants in a coronavirus disease 2019 convalescent plasma donation study that may benefit optimal collection methods in the future. Methods: Data from a convalescent plasma donation study from April 30, 2020 to November 5, 2021 were collected and analyzed. After August 23, 2021, an interim analysis of factors linked to higher antibody titers led us to restrict our participant recruitment criteria to participants who were within 4 months of disease onset and to patients who were otherwise most likely to have sufficiently high antibody titers. Overall, 1299 samples from 1179 patients were analyzed. Results: Over the duration of the study, 35.9% of the samples were deemed eligible for convalescent plasma collection. The overall eligibility rate initially declined, dipping to <20% after one year. During this period, the proportion of enrolled samples from patients who had severe illness also declined, and the proportion of samples from participants who were >120 days post disease onset increased. After the addition of days from onset and vaccination status to our participant recruitment criteria, the eligibility rate improved significantly. Conclusions: As outbreaks of emerging infectious disease occur, it is desirable to construct and implement a scheme for convalescent plasma donation promptly and to monitor the eligibility rate over time. If it declines, promptly analyze and resolve the associated factors. Additionally, vaccine development and infection prevalence are likely to influence the effective recruitment of participants with high antibody titers.

Indexed as

convalescent plasmaCOVID-19emerging infectious diseasepandemicre-emerging infectious disease

Identifiers

PMID37842585
PMCPMC10568336
OpenAlexW4387159225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.